SAN JOSE, Calif., Feb. 26,
2015 /PRNewswire/ -- BD Life Sciences, a segment of BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, and Cellular Research, an innovative
company focused on enabling high-resolution biology, today
announced that they will be jointly promoting their unique
solutions for highly multiplexed cell isolation and single-cell
gene expression analysis.
The companies are promoting BD's powerful BD FACS™ single-cell
sorting instrumentation and software with Cellular Research's
Precise™ assays based on Molecular Indexing™ technology to offer
customers an integrated workflow for measuring both nucleic acid
and protein expression in cellular subtypes.
"We believe that this combination of unique capabilities,
Molecular Indexing of genetic markers from Cellular Research and
single-cell sorting using protein markers from BD, will
significantly increase the ability to identify and analyze cell
populations for basic and clinical research," said Stephen Fodor, Ph.D., Chief Executive Officer of
Cellular Research.
Cellular Research has developed Precise, a highly multiplexed
molecular and sample barcoding technology, whereby each transcript
in each plated cell is uniquely barcoded during incorporation into
one sequencing library. Precise encoding plates can also be
multiplexed, enabling up to 4,608 single cells to be prepared into
one single sequencing library and reaction.
The combined workflow enables cells to be individually sorted
into 96- or 384- well Precise encoding plates using the BD FACS™
instruments and software. "Today's announcement represents an
exciting step forward for researchers engaged in single-cell
genomic analysis," said Claude Dartiguelongue, Worldwide President,
BD Biosciences. "The efficiency of identifying and isolating single
cells greatly increases the throughput of cells available for
transcriptome analysis, creating the potential, now within reach of
investigators, to analyze gene expression targets in many thousands
of individual cells."
Initial results and findings will be presented during the
16th annual Advances in Genome Biology and Technology
(AGBT) meeting held in Marco Island,
Florida, February 25-28. The
presentation is titled: "A Comprehensive High Throughput Single
Cell Analysis Workflow Combining Proteomic and Genomic
Information: Flow sorting, single cell tagging, molecular
barcoding, library preparation, and sequencing analysis."
About BD
BD is a leading medical technology company
that partners with customers and stakeholders to address many of
the world's most pressing and evolving health needs. Our innovative
solutions are focused on improving drug delivery, enhancing the
diagnosis of infectious diseases and cancers, supporting the
management of diabetes and advancing cellular research. We are more
than 30,000 associates in 50 countries who strive to fulfill our
purpose of "Helping all people live healthy lives" by advancing the
quality, accessibility, safety and affordability of healthcare
around the world. For more information, please visit
www.bd.com.
About Cellular Research
Cellular Research, Inc. is a
biotechnology research and development company founded by
innovators from Silicon Valley and Stanford University. Our
mission is to develop and commercialize a new generation of highly
sensitive life science technologies and products. In addition
to introducing a portfolio of research products, the Company has an
active partnership program with pharmaceutical and diagnostics
companies advancing clinical applications. For more
information, please
visit http://www.cellular-research.com/.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the planned joint collaboration activities between
Cellular Research Inc. and BD Life Sciences – Biosciences, and the
capabilities anticipated to be provided by the jointly developed
workflows. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: risks associated with keeping pace with rapidly
changing technology and customer requirements; risks that new
market opportunities may not develop as quickly as expected; risks
associated with competition in marketing and selling products; and
other risks set forth in BD's and Cellular Research Inc. respective
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. BD and
Cellular Research, Inc. disclaim any obligation to update these
forward-looking statements.
Trademarks
BD, BD Logo and BD FACS are trademarks of
Becton, Dickinson and Company.
Cellular Research, Cellular Research Logo, Precise and Molecular
Indexing are trademarks of Cellular Research, Inc.
Contact:
BD
Matthew
Coppola
Public Relations
(201)
847-7370
Matthew_R_Coppola@bd.com
Cellular Research
Martin
Pieprzyk
Marketing
Department
Mpieprzyk@cellular-research.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-and-cellular-research-announce-co-marketing-efforts-for-single-cell-sequencing-300042085.html
SOURCE BD (Becton, Dickinson and Company)